Mass spectrometry could solve pharma riddle
Pharma researchers could gain from mass spectrometry-based studies

Bioanalytical

Mass spectrometry could solve pharma riddle

15 Jun, 2010

Published over 16 years ago. See the latest and most current information on Bioanalytical.

The riddle of what happens at the carboxy-termini of protein clippings has puzzled pharma professionals for some time.

While the amino-termini of protein clippings have been successfully analysed, pharma researchers have thus far failed to find a satisfactory way to investigate the clippings' other ends.

However, mass spectrometry may provide the answer, as scientists at Albert-Ludwigs-Universitaet Freiburg have revealed.

The discovery could hold promise for the research of medical conditions - such as the role of cathepsin proteases in cancer development.

Using mass spectrometry as part of a multi-stage process, the scientists identified carboxy-terminal sequences following proteolysis.

They claim to have unearthed a relatively high rate of proteolysis, as 40 per cent of carboxy-termini identified are believed to have been created through molecular cleavage.

The University recently hosted a conference of about 350 scientists who discussed issues relating to systems biology and, in particular, generalising research at the cellular level to be applied to whole mammalian organisms.

Latest News

Explore Our Other Sites

Labmate Online
Fungal and bacterial triggers may be drivers in steroid-resistant asthma
Explore more Arrow
Envirotech Online
New oxygen sensor range targets OEM gas detection applications
Explore more Arrow
Pollution Solutions Online
Skid-mounted systems target oxygen and moisture removal for renewable natural gas
Explore more Arrow
Petro Online
Automated freezing-point testing arrives for jet fuel: what ASTM D8615 changes for lab workflows
Explore more Arrow